{
  "docId": "019de517-1302-72c9-b1b1-402f68725e8a",
  "docSlug": "8240d0b9060d59c07a4e5f5063c97322",
  "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 11,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 12,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/5",
  "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a",
  "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json",
  "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.445,
        "w": 0.369,
        "x": 0.574,
        "y": 0.242
      },
      "kind": "list",
      "text": "Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study²\nIn a sample of ~17M people in a large U.S. commercial health insurance plan, 2.7% were IC\n~14% of the IC people were diagnosed with COVID-19 and, of those, 24% were hospitalized\nIC people had long hospital stays and high costs associated with COVID-19, with a mean cost of $64,029 per patient and mean length of hospitalization stay of 15 days",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dc15908-07d9-4974-90dd-bf78d40f0b7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.502,
        "w": 0.42,
        "x": 0.064,
        "y": 0.242
      },
      "kind": "list",
      "text": "Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study¹\nIn a sample of ~12M people in England, 3.9% were immunocompromised (IC)\nAlthough only 3.9% of the population, IC people accounted for 22% of COVID-19 hospitalizations and 24% of COVID-19 deaths – even though >80% of the IC population had received ≥3 COVID-19 vaccines\nCertain IC people (e.g., solid organ and stem cell transplant recipients and those recently treated for blood cancers), had greater than 10-fold increases in risk compared to those without these conditions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d46866a2-e795-4e1b-8c46-da47554fde27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.44,
        "x": 0.045,
        "y": 0.954
      },
      "kind": "source-note",
      "text": "1. Evans Lancet Reg 2023; 2. Ketkar Curr Med Res Opin 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3928d1a4-9c94-4e97-8769-520331898d31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.069,
        "w": 0.894,
        "x": 0.055,
        "y": 0.83
      },
      "kind": "title",
      "text": "Despite the availability of vaccines, immunocompromised people remain at higher risk for severe COVID-19 outcomes and need additional therapeutic options to protect against COVID-19",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8d12e83-5b5d-42c1-84ae-6cf88be356a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.899,
        "x": 0.045,
        "y": 0.06
      },
      "kind": "title",
      "text": "THE NEED TO PROTECT IMMUNOCOMPROMISED INDIVIDUALS FROM COVID-19 IS CLEAR AND URGENT",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f6c7531-2504-4c24-82f4-64514458e62b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "478efb00-635d-4412-b6bc-5ad4d1413924",
      "evidence": "title/action-title: Despite the availability of vaccines, immunocompromised people remain at higher risk for severe COVID-19 outcomes and need additional therapeutic options to protect against COVID-19",
      "confidence": 0.8
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "20ea3e97-172c-45ab-9254-18d32c0a64ee",
      "evidence": "Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study¹",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "b55d8bab-3721-421b-b288-fbc544a321e0",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The problem statement highlights the urgent need for protection against COVID-19",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889",
      "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction",
      "position": 0,
      "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}